Evidence map›Paper›PMID 28193250›Full record

ArticleParasites & vectors2017

A novel modified-indirect ELISA based on spherical body protein 4 for detecting antibody during acute and long-term infections with diverse Babesia bovis strains.

Chungwon J Chung, Carlos E Suarez, Carey L Bandaranayaka-Mudiyanselage, Chandima-Bandara Bandaranayaka-Mudiyanselage, Joanna Rzepka, T J Heiniger, Grace Chung, Stephen S Lee, Ethan Adams, Grace Yun and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Role ofFrontiers in cellular and infection microbiology · 2024
    Article
  3. Frontiers in cellular and infection microbiology · 2023
    Article
  4. The GP-45 Protein, a Highly Variable Antigen fromPathogens (Basel, Switzerland) · 2022
    Article
  5. Comparison of high throughput RNA sequences betweenFrontiers in cellular and infection microbiology · 2022
    Article
  6. Transcriptome dataset ofData in brief · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chungwon J ChungWashington State University, Pullman, WA, USA. chungcw@vetmed.wsu.edu.
Carlos E SuarezWashington State University, Pullman, WA, USA.
Carey L Bandaranayaka-MudiyanselageVMRD, Inc., Pullman, WA, USA.
Chandima-Bandara Bandaranayaka-MudiyanselageVMRD, Inc., Pullman, WA, USA.
Joanna RzepkaVMRD, Inc., Pullman, WA, USA.
T J HeinigerVMRD, Inc., Pullman, WA, USA.
Grace ChungVMRD, Inc., Pullman, WA, USA.
Stephen S LeeUniversity of Idaho, Moscow, ID, USA.
Ethan AdamsVMRD, Inc., Pullman, WA, USA.
Grace YunVMRD, Inc., Pullman, WA, USA.
Susan J WaldronTick Fever Center, Wacol, Australia.
Washington State University · USUniversity of Idaho · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCattle persistently infected with Babesia bovis are reservoirs for intra- and inter-herd transmission. Since B. bovis is considered a persistent infection, developing a reliable, high-throughput assay that detects antibody during all stages of the infection could be pivotal for establishing better control protocols.

methodsA modified indirect enzyme-linked immunosorbent assay (MI-ELISA) was developed using the spherical body protein-4 (SBP4) of B. bovis to detect antibody against diverse strains through all infection stages in cattle. This SBP4 MI-ELISA was evaluated for sensitivity and specificity against field sera from regions with endemic and non-endemic B. bovis. Sera were also evaluated from cattle infected experimentally with various doses and strains during acute and persistent infection with parasitemia defined by nested PCR.

resultsThe format variables for SBP4 MI-ELISA were optimized and the cutoff for positive and negative interpretation was determined based on receiver operating characteristic curve analysis using B. bovis positive and negative sera tested in the reference immunofluorescence assay (IFA). The diagnostic specificity of the SBP4 MI-ELISA using IFA-negative sera collected from Texas was 100%, significantly higher than the cELISA (90.4%) based on an epitope in the rhoptry-associated protein-1 (RAP-1 cELISA). The diagnostic sensitivity of the SBP4 MI-ELISA was 98.7% using the IFA-positive sera collected from several areas of Mexico, in contrast to that of the RAP-1 cELISA at 60% using these same sera. In cattle infected with low and high doses of three B. bovis strains, the SBP4 MI-ELISA remained antibody positive for 11 months or more after initial detection at 10 to 13 days post-inoculation. However, the RAP-1 cELISA did not reliably detect antibody after eight months post-inoculation despite the fact that parasitemia was occasionally detectable by PCR. Furthermore, initial antibody detection by RAP-1 cELISA in low-dose infected animals was delayed approximately nine and a half days compared to the SBP4 MI-ELISA.

conclusionsThese results demonstrate excellent diagnostic sensitivity and specificity of the novel SBP4 MI-ELISA for cattle with acute and long-term carrier infections. It is posited that use of this assay in countries that have B. bovis-endemic herds may be pivotal in preventing the spread of this disease to non-endemic herds.

Indexed as

AnimalsAntibodies, ProtozoanBabesia bovisBabesiosisCattleCattle DiseasesEnzyme-Linked Immunosorbent AssayMexicoPolymerase Chain ReactionProtozoan ProteinsSensitivity and SpecificitySerologic TestsTexasAntibodies, ProtozoanProtozoan ProteinsBabesia bovisDiagnosisModified indirect enzyme-linked immunosorbent assaySpherical body protein-4

Identifiers

PMID28193250
PMCPMC5307855
OpenAlexW2588501449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.